What is AKANDA CORP's earnings per share (EPS)?

AKANDA CORP (AKAN) reported diluted earnings per share of $-669.58 for fiscal year 2025. This represents a -21224.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AKANDA CORP Financials

AKAN

Source SEC Filings (10-K/10-Q) Updated Jun 9, 2026 Currency USD FYE June

This page shows AKANDA CORP (AKAN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AKAN FY2024 2026-06-09

External financing is still the operating engine as cash burn overwhelms a modest sales rebound and reshapes the balance sheet.

FY2024 looks less strained than FY2023 because financing inflows of $9.0M lifted cash to $3.8M, helped restore positive equity, and cut liabilities sharply. But free cash flow was still -$6.1M, so the cleaner balance sheet reflects recapitalization more than self-funding; liquidity improved faster than the underlying business economics.

The tight link between net loss of $4.1M and operating cash outflow of -$4.0M shows losses are being paid in cash, not mainly created by accounting adjustments. That makes reported earnings a fairly direct map of liquidity pressure, which matters more here than margin analysis because revenue is still under $1M.

Sales nearly doubled from $424K to $837K, but that scale still does not cover the company's cash needs. The gap widened because capital spending reached $2.1M, pushing free cash burn well below operating burn and signaling that FY2024 included real reinvestment on top of day-to-day losses.

Financial Health Signals

Financial Profile 18/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of AKANDA CORP's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

AKANDA CORP's revenue declined 69.2% year-over-year, from $837K to $258K. This contraction results in a growth score of 0/100.

Liquidity

AKANDA CORP's current ratio of 0.58 is below the typical benchmark, resulting in a score of 6/100. However, the company holds substantial cash reserves (62% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow

While AKANDA CORP generated -$6.7M in operating cash flow, capex of $1.2M consumed most of it, leaving -$8.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

1/9

AKANDA CORP passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$258K

YoY-69.2%

5Y CAGR+162.7%

AKANDA CORP generated $258K in revenue in fiscal year 2025. This represents a decrease of 69.2% from the prior year.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-669.58

YoY-21224.2%

AKANDA CORP earned $-669.58 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 21224.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$8.0M

YoY-31.0%

AKANDA CORP generated -$8.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 31.0% from the prior year.

Cash & Debt

$3.8M

YoY+0.0%

5Y CAGR+209.6%

AKANDA CORP held $3.8M in cash against $209K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY-3.1%

AKANDA CORP had 2M shares outstanding in fiscal year 2025. This represents a decrease of 3.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$1.2M

YoY-41.2%

5Y CAGR+23.0%

AKANDA CORP invested $1.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 41.2% from the prior year.

AKAN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$258K-69.2%	$837K+97.5%	$424K-83.8%	$2.6M+6223.0%	$41K+1909.3%	$2K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$1.1M+2179.3%	-$54K-100.4%	$11.9M	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.1M+87.3%	-$32.3M-176.9%	-$11.7M-43.4%	-$8.1M-253.4%	-$2.3M
EPS (Diluted)	$-669.58-21224.2%	$-3.14+95.2%	$-65.92-2297.1%	$-2.75-1733.3%	$-0.15	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q2'23	Q4'22	Q2'22	Q2'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AKAN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.2M-21.7%	$7.9M-10.5%	$8.8M-77.3%	$39.0M+384.7%	$8.0M+88.2%	$4.3M
Current Assets	$3.6M-28.7%	$5.1M+180.0%	$1.8M-52.7%	$3.8M-4.0%	$4.0M+3019.3%	$128K
Cash & Equivalents	$3.8M0.0%	$3.8M+3992.5%	$94K-63.3%	$256K-92.7%	$3.5M+25784.1%	$14K
Inventory	N/A	N/A	$1.3M+21.7%	$1.1M	N/A	$611
Accounts Receivable	$1.4M+277.8%	$371K+30.2%	$285K-77.0%	$1.2M+409.8%	$242K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.2M+400.0%	$3.6M-71.3%	$12.7M+4.7%	$12.1M+18.0%	$10.2M+10.1%	$9.3M
Current Liabilities	$6.2M+70.4%	$3.6M-64.2%	$10.2M+8.8%	$9.3M+13.1%	$8.3M+202.7%	$2.7M
Long-Term Debt	$209K+595.6%	$30K	N/A	$117K-94.1%	$2.0M-23.8%	$2.6M
Total Equity	-$12.0M-380.4%	$4.3M+211.7%	-$3.8M-114.2%	$26.9M+1321.9%	-$2.2M+56.3%	-$5.0M
Retained Earnings	-$103.1M-79.4%	-$57.5M-7.7%	-$53.4M-153.0%	-$21.1M-58.6%	-$13.3M-157.5%	-$5.2M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q2'23	Q4'22	Q2'22	Q2'21
Total Assets	$6.2M-21.5%	$7.9M-20.6%	$10.0M+12.7%	$8.8M-77.3%	$39.0M-10.3%	$43.5M+440.4%	$8.0M+88.2%	$4.3M
Current Assets	$3.6M-29.4%	$5.1M-33.6%	$7.6M+321.6%	$1.8M-52.7%	$3.8M-45.0%	$6.9M+74.4%	$4.0M+3019.3%	$128K
Cash & Equivalents	$2.5M-34.2%	$3.8M-36.3%	$6.0M+6325.5%	$94K-63.3%	$256K-93.5%	$3.9M+12.5%	$3.5M+25784.1%	$14K
Inventory	N/A	N/A	N/A	$1.3M+21.7%	$1.1M+18.0%	$896K	N/A	$611
Accounts Receivable	$4K-98.9%	$371K+18.9%	$312K+9.6%	$285K-77.0%	$1.2M+70.0%	$727K+199.9%	$242K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.9M-19.9%	$3.6M-32.6%	$5.4M-57.4%	$12.7M+4.7%	$12.1M+36.8%	$8.8M-13.7%	$10.2M+10.1%	$9.3M
Current Liabilities	$2.8M-21.8%	$3.6M-32.6%	$5.4M-47.0%	$10.2M+8.8%	$9.3M+49.0%	$6.3M-24.1%	$8.3M+202.7%	$2.7M
Long-Term Debt	$71K+136.2%	$30K	N/A	N/A	$117K	N/A	$2.0M-23.8%	$2.6M
Total Equity	$3.3M-22.8%	$4.3M-6.4%	$4.6M+219.4%	-$3.8M-114.2%	$26.9M-22.3%	$34.6M+1673.5%	-$2.2M+56.3%	-$5.0M
Retained Earnings	-$58.3M-1.4%	-$57.5M-2.5%	-$56.0M-5.0%	-$53.4M-153.0%	-$21.1M-75.4%	-$12.0M+9.6%	-$13.3M-157.5%	-$5.2M

AKAN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.7M-69.1%	-$4.0M-165.3%	-$1.5M+86.9%	-$11.5M-74.9%	-$6.6M	N/A
Capital Expenditures	$1.2M-41.2%	$2.1M+139589.6%	$2K-99.5%	$311K-46.1%	$576K+31.3%	$439K
Free Cash Flow	-$8.0M-31.0%	-$6.1M-304.7%	-$1.5M+87.2%	-$11.8M-65.1%	-$7.1M	N/A
Investing Cash Flow	-$7.5M-633.3%	-$1.0M-4183.0%	$25K+100.6%	-$4.2M-631.8%	-$576K-33.4%	-$432K
Financing Cash Flow	$11.7M+29.9%	$9.0M+504.7%	$1.5M-89.5%	$14.1M+25.8%	$11.2M+987.2%	$1.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q2'23	Q4'22	Q2'22	Q2'21
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AKAN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-489.6%+7128.2pp	-7617.7%-7172.7pp	-445.0%+19180.9pp	-19625.9%+91944.0pp	-111569.9%
Return on Equity	N/A	-95.8%	N/A	-43.3%	N/A	N/A
Return on Assets	N/A	-51.8%+313.3pp	-365.1%-335.2pp	-29.9%+71.2pp	-101.1%-47.2pp	-53.8%
Current Ratio	0.58-0.8	1.39+1.2	0.18-0.2	0.41-0.1	0.48+0.4	0.05
Debt-to-Equity	N/A	0.01+3.3	-3.31-3.3	0.00+0.9	-0.90-0.4	-0.52
FCF Margin	-3085.6%-2359.1pp	-726.5%-372.0pp	-354.5%+95.2pp	-449.7%+16768.2pp	-17217.9%	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q2'23	Q4'22	Q2'22	Q2'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.25-0.1	1.39-0.0	1.41+1.2	0.18-0.2	0.41-0.7	1.11+0.6	0.48+0.4	0.05
Debt-to-Equity	0.02+0.0	0.01-1.2	1.18+4.5	-3.31-3.3	0.00-0.3	0.26+1.2	-0.90-0.4	-0.52
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$12.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.58), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Universe Pharmaceuticals Inc UPC

$4.1M

PRF Technologies Ltd. PRFX

$4.1M

SHUTTLE PHARMACTCLS HLDGS INC SHPH

$2.1M

Redhill Biopharm RDHL

$4.9M

Inmed Pharmaceuticals Inc INM

$5.2M

Frequently Asked Questions

What is AKANDA CORP's annual revenue?

AKANDA CORP (AKAN) reported $258K in total revenue for fiscal year 2025. This represents a -69.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AKANDA CORP's revenue growing?

AKANDA CORP (AKAN) revenue declined by 69.2% year-over-year, from $837K to $258K in fiscal year 2025.

How much debt does AKANDA CORP have?

As of fiscal year 2025, AKANDA CORP (AKAN) had $3.8M in cash and equivalents against $209K in long-term debt.

What is AKANDA CORP's free cash flow?

AKANDA CORP (AKAN) generated -$8.0M in free cash flow during fiscal year 2025. This represents a -31.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AKANDA CORP's operating cash flow?

AKANDA CORP (AKAN) generated -$6.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are AKANDA CORP's total assets?

AKANDA CORP (AKAN) had $6.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are AKANDA CORP's capital expenditures?

AKANDA CORP (AKAN) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does AKANDA CORP have outstanding?

AKANDA CORP (AKAN) had 2M shares outstanding as of fiscal year 2025.

What is AKANDA CORP's current ratio?

AKANDA CORP (AKAN) had a current ratio of 0.58 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is AKANDA CORP's cash runway?

Based on fiscal year 2025 data, AKANDA CORP (AKAN) had $3.8M in cash against an annual operating cash burn of $6.7M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is AKANDA CORP's Piotroski F-Score?

AKANDA CORP (AKAN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

How financially healthy is AKANDA CORP?

AKANDA CORP (AKAN) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.